Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 754

1.

Applicability of sentinel lymph node biopsy in papillary thyroid cancer.

Delgado-Oliver E, Vidal-Sicart S, Martínez D, Squarcia M, Mora M, Hanzu FA, Halperin I, Fuster D, Fondevila C, Vidal-Perez Ó.

Q J Nucl Med Mol Imaging. 2018 Jul 9. doi: 10.23736/S1824-4785.18.03097-2. [Epub ahead of print]

PMID:
29999291
2.

Serotonin 1A receptor density measured by F18-Mefway PET/CT in mesiotemporal cortex and raphe does not discriminate therapeutic response in patients with major depressive episode.

Barth M, Dunzinger A, Wimmer I, Winkler J, Rittmannsberger H, Nader M, Pichler R.

Q J Nucl Med Mol Imaging. 2018 Jun 14. doi: 10.23736/S1824-4785.18.03039-X. [Epub ahead of print]

PMID:
29916219
3.

Investigational PET tracers for high grade gliomas.

Choudhary G, Langen KJ, Galldiks N, Mcconathy J.

Q J Nucl Med Mol Imaging. 2018 Jun 4. doi: 10.23736/S1824-4785.18.03105-9. [Epub ahead of print]

PMID:
29869489
4.

Radiomics derived from amino acid PET and conventional MRI in patients with high-grade gliomas.

Lohmann P, Kocher M, Steger J, Galldiks N.

Q J Nucl Med Mol Imaging. 2018 Jun 4. doi: 10.23736/S1824-4785.18.03095-9. [Epub ahead of print]

PMID:
29869488
5.

Biological PET-guided adaptive radiotherapy for dose escalation in head and neck cancer: a systematic review.

Hamming-Vrieze O, Navran A, Al-Mamgani A, Vogel WV.

Q J Nucl Med Mol Imaging. 2018 Jun 4. doi: 10.23736/S1824-4785.18.03087-X. [Epub ahead of print]

PMID:
29869487
6.

Image-guided adaptive radiotherapy in patients with locally advanced NSCLC: the art of PET.

Grootjans W, de Geus-Oei LF, Bussink J.

Q J Nucl Med Mol Imaging. 2018 Jun 4. doi: 10.23736/S1824-4785.18.03084-4. [Epub ahead of print]

PMID:
29869486
7.

18F-FDG-PET/CT guided external beam radiotherapy volumes in inoperable uterine cervical cancer.

Adam JA, Arkies H, Hinnen K, Stalpers LJ, van Waesberghe JH, Stoker J, van Os R, Laan JJ, Mom CH, van Eck-Smit BL.

Q J Nucl Med Mol Imaging. 2018 Jun 4. doi: 10.23736/S1824-4785.18.03083-2. [Epub ahead of print]

PMID:
29869485
8.

PET imaging in adaptive radiotherapy of gastrointestinal tumours.

Bulens P, Thomas M, Deroose CM, Haustermans K.

Q J Nucl Med Mol Imaging. 2018 Jun 4. doi: 10.23736/S1824-4785.18.03081-9. [Epub ahead of print]

PMID:
29869484
9.

PET imaging in adaptive radiotherapy of prostate tumors.

Beuthien-Baumann B, Koerber SA.

Q J Nucl Med Mol Imaging. 2018 Jun 4. doi: 10.23736/S1824-4785.18.03080-7. [Epub ahead of print]

PMID:
29869483
10.

Neuroimaging in patients with high-grade gliomas.

Galldiks N.

Q J Nucl Med Mol Imaging. 2018 May 16. doi: 10.23736/S1824-4785.18.03102-3. [Epub ahead of print] No abstract available.

PMID:
29781593
11.

Functional magnetic resonance imaging in glioma patients: from clinical applications to future perspectives.

Volz LJ, Kocher M, Lohmann P, Shah NJ, Fink GR, Galldiks N.

Q J Nucl Med Mol Imaging. 2018 May 14. doi: 10.23736/S1824-4785.18.03101-1. [Epub ahead of print]

PMID:
29761998
12.

Evaluation of multifunctional imaging parameters in gastro-oesophageal cancer using F-18-FDG-PET/CT with integrated perfusion CT.

Sah BR, Leissing CA, Delso G, Ter Voert EE, Krieg S, Leibl S, Schneider PM, Reiner CS, Hüllner MW, Veit-Haibach P.

Q J Nucl Med Mol Imaging. 2018 May 10. doi: 10.23736/S1824-4785.18.03067-4. [Epub ahead of print]

PMID:
29745630
13.

PSA levels as a predictor of 68Ga PSMA PET/CT positivity in patients with prostate cancer?

Soydal C, Urun Y, Suer E, Nak D, Ozkan E, Kucuk ON.

Q J Nucl Med Mol Imaging. 2018 May 10. doi: 10.23736/S1824-4785.18.03056-X. [Epub ahead of print]

PMID:
29745629
14.

Imaging in the evaluation of response to treatment in oncology.

Bisi G.

Q J Nucl Med Mol Imaging. 2018 Jun;62(2):127-128. doi: 10.23736/S1824-4785.18.03071-6. No abstract available.

15.

Emerging topics and practical aspects for an appropriate use of amyloid PET in the current italian context.

Nobili F, Cagnin A, Calcagni ML, Chincarini A, Guerra UP, Morbelli S, Padovani A, Paghera B, Pappatà S, Parnetti L, Sestini S, Schillaci O.

Q J Nucl Med Mol Imaging. 2018 Apr 24. doi: 10.23736/S1824-4785.18.03069-8. [Epub ahead of print]

PMID:
29697220
16.

2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.

Salvatore B, Fonti R, De Renzo A, Pellegrino S, Ferrara IL, Mainolfi CG, Marano L, Selleri C, Pane F, Del Vecchio S, Pace L.

Q J Nucl Med Mol Imaging. 2018 Apr 24. doi: 10.23736/S1824-4785.18.03043-1. [Epub ahead of print]

PMID:
29697219
17.

Total FDG lesion number on PET/CT predicts survival of esophageal carcinoma patients with recurrence following curative surgery.

Kim SJ, Hyun SH, Moon SH, Cho YS, Yi HK, Shim YM, Choi JY, Kim BT, Lee KH.

Q J Nucl Med Mol Imaging. 2018 Apr 24. doi: 10.23736/S1824-4785.18.03041-8. [Epub ahead of print]

PMID:
29697218
18.

Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatropin case.

Bracke N, Janssens Y, Wynendaele E, Tack L, Maes A, van de Wiele C, Sathekge M, De Spiegeleer B.

Q J Nucl Med Mol Imaging. 2018 Apr 24. doi: 10.23736/S1824-4785.18.03025-X. [Epub ahead of print]

PMID:
29697217
19.

Overview on current treatment standards in high-grade gliomas.

Pellerino A, Franchino F, Soffietti R, Rudà R.

Q J Nucl Med Mol Imaging. 2018 Apr 26. doi: 10.23736/S1824-4785.18.03096-0. [Epub ahead of print]

PMID:
29696949
20.

Role of amino acid PET in HGGs: limitations and perspectives.

Verger A, Arbizu J, Law I.

Q J Nucl Med Mol Imaging. 2018 Apr 26. doi: 10.23736/S1824-4785.18.03092-3. [Epub ahead of print]

PMID:
29696948

Supplemental Content

Loading ...
Support Center